This page shows what was measured, who it was measured in, and what that does not settle.
What Cyclophosphamide (anhydrous) does in the body
Nephrotic syndrome
From the FDA-approved label: The mechanism of action has not been fully characterized. However, cross-linking of tumor cell DNA may be involved. The active alkylating metabolites of cyclophosphamide interfere with the growth of susceptible rapidly proliferating malignant cells.
What happened in people
RNAWiki has not yet published a reviewed conclusion for this use.
§ A fixed RNAWiki sentence
Where this came from
Wording RNAWiki always uses, not a finding about this substance.
No reviewed claim names a result for any goal on this record.
No source is stored against this line.
The limit that matters most
Not recorded.
Where it acts
Not recorded.
Kind of result
No result is published, so no kind of result applies yet
Supervision
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
What the registries record it as
The substance registry classes this as chemical.
FDA substance registry · 8N3DW7272P · read 2026-08-29
Its recorded molecular formula is C7H15Cl2N2O2P•H2O, weighing 279.1.
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
Where each sentence above came from
No recorded sentence describes the change this makes in a way that stands on its own. The page opens with what it is taken for instead, and the recorded explanation follows below.
Shown as the opening line on this page.
No statement of the main limit is recorded.
The four opening statements run to 53 words.
Words this page uses
Four words worth knowing first
Chosen from what this page shows, with each one explained before the word it depends on.
Biomarker
A biomarker is a number from a test that stands in for something about health.
A picture of it, and where the picture fails
A biomarker is like a fuel gauge.
Where that stops being true. A gauge is wired to the tank. Many biomarkers are only loosely tied to health.
What people get wrong. A better number is read as a better life. Several medicines improved a number and helped nobody.
A measurable indicator used as a substitute for a clinical outcome of interest.
Placebo
A placebo is a dummy treatment given so the real one can be compared with it.
A picture of it, and where the picture fails
A placebo is like a blank control in an experiment.
Where that stops being true. A blank does nothing. People given a placebo often do get better.
What people get wrong. A placebo effect is read as imaginary. The improvement is measured and real.
An inactive intervention matched in appearance to the test intervention, used to control for non-specific effects.
Comparator
A comparator is whatever the treatment was measured against.
A picture of it, and where the picture fails
It is like the other runner in a race.
Where that stops being true. A race has one winner. A study can show both arms improved.
What people get wrong. Results are read without asking what the other group got. Beating nothing is not beating a treatment.
The control condition against which the experimental intervention is assessed.
What happened in people◇Read from sources, not yet reviewed
What happened in people
Each card is one study: the exact question it asked, who was in it, and whether it showed what it set out to show.
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization
✗ The study did not show it
Who was studied
NCT01190930
How many people
9350
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Disease free survival (DFS) in randomization eligible patients with higher risk features (SR-High) or standard risk average (SR-Avg) B-ALL patients based on randomization with addition of blinatumomab
✗ The study did not show it
Who was studied
NCT03914625
How many people
6720
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Event-free survival
✗ The study did not show it
Who was studied
NCT01117441
How many people
6136
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast Cancer
✗ The study did not show it
Who was studied
NCT00002582
How many people
6000
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
A number that stands in for health
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
Post-induction 5-year event-free survival (EFS)
✗ The study did not show it
Who was studied
NCT03959085
How many people
5951
Study design
Phase 3
Compared against
Not recorded for this study
Kind of result
Living longer, or avoiding a major event
What was found
Result not recorded on this page
Repeated elsewhere
Unreplicated
What this does not prove. A study that did not show an effect does not show that no effect exists anywhere.
The limits of this study, and where it came from
Main limit. No limitation is recorded for this study.
How far it carries. This study is recorded from the curated record, not from the registry match.
Form and route. Oral
Interval reported. Not recorded in this summary
Written into the record, not signed off as a reviewed claim.
openFDA Drugs@FDA · a recorded source, not a stored snapshot
openFDA NDC Directory · a recorded source, not a stored snapshot
openFDA SPL label · a recorded source, not a stored snapshot
PubChem PUG-REST · a recorded source, not a stored snapshot
What we know
RNAWiki holds 6 written-up human studies for this substance, each with the question it asked.
How we know it
Each card names the study, the number of people and what the study set out to measure.
What this does not prove
These summaries were written by a person and have not been signed off as reviewed claims.
Why it matters
A study that failed is as informative as one that worked, and both are here.
What we still do not know
No reviewed claim exists, so no exact population, effect size or interval is published yet.
What is missing or unclear◇Read from sources, not yet reviewed
Were people like you studied?
RNAWiki cannot tell whether a study fits you. It can show who was in it, and where the result stops carrying.
Who was studied
People similar to this profile were included.
Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Disease s: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma ( 1.1 ) Minimal Change…
Who is missing from the studies
Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What the label states about particular groups
On pediatric, the label states: “The safety and effectiveness of cyclophosphamide have been established in pediatric patients and information on this use is discussed throughout the labeling.”
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
On older people, the label states: “There is insufficient data from clinical studies of cyclophosphamide available for patients 65 years of age and older to determine whether they respond differently than younger patients.”
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
On people who are pregnant, the label states: “Risk Summary Based on its mechanism of action and published reports of effects in pregnant patients or animals, Cyclophosphamide for Injection can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology ( 12.1 ) and Nonclinical Toxicology ( 13.1 )] .”
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
On people who are breastfeeding, the label states: “Risk summary Cyclophosphamide is present in breast milk.”
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
On people with reduced liver function, the label states: “Patients with severe hepatic impairment have reduced conversion of cyclophosphamide to the active 4-hydroxyl metabolite, potentially reducing efficacy [see Clinical Pharmacology ( 12.3 )] .”
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
On people with reduced kidney function, the label states: “In patients with severe renal impairment, decreased renal excretion may result in increased plasma levels of cyclophosphamide and its metabolites, which may increase toxicity [see Clinical Pharmacology ( 12.3 )] .”
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
Where the result stopped carrying
This is a scope explorer, not a diagnosis engine.
It shows who was studied so you can see whether people similar to you were included.
RNAWiki cannot tell whether a study fits you. It can show who was in it.
What it would be like to take◇Read from sources, not yet reviewed
Why it might seem to do nothing
A real effect and a noticed effect are different things. These are the recorded reasons the two come apart.
It was studied in different people
The people in the studies were not much like the reader.
On this record: Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
The evidence may simply be wrong
Small early studies often do not hold up.
On this record: RNAWiki has not yet published a reviewed conclusion for this use.
Other reasons RNAWiki checked and found nothing for (11)
It was studied for a different goal
The studies measured something else entirely. Nothing in this record points to this reason.
A different form was studied
The studied form is not the form on the shelf. Nothing in this record points to this reason.
There was nothing to correct
Where a level is already normal, topping it up may change nothing. Nothing in this record points to this reason.
Something else had to happen too
In the studies it was paired with training, a diet or another treatment. Nothing in this record points to this reason.
The change is too small to feel
A real change can still sit below what a person notices. Nothing in this record points to this reason.
Day-to-day swing hides it
Sleep, food, stress and time of day move most numbers more than this would. Nothing in this record points to this reason.
Not enough time yet
The studies ran longer than the person has waited. Nothing in this record points to this reason.
It was not taken as studied
Missed days change the result, and studies count them. Nothing in this record points to this reason.
Something else changed at the same time
Two changes at once cannot be told apart afterwards. Nothing in this record points to this reason.
The product may not be what it says
Contents of a sold product are not always what the label states. Nothing in this record points to this reason.
No recorded reason
RNAWiki has nothing stored that would explain it. Nothing in this record points to this reason.
None of these is a reason to take more. Taking more is not a step this page ever suggests.
What it would be like to take◇Read from sources, not yet reviewed
What taking it involves
The recorded facts about getting hold of it and using it. Nothing here is a suggestion about what you should do.
How it is supplied
Prescription only
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Read from the recorded approval status.
No source is stored against this line.
Form and route
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form and route recorded on this substance.
No source is stored against this line.
Who oversees it
Professional supervision is normally required. A regulator classifies this substance in a way that restricts how it is supplied.
❝ Quoted from a source
Where this came from
Copied from a source RNAWiki stored, with the source named.
Suppression classes recorded: S1, S3, S4.
No source is stored against this line.
What is in the pack
Sold as capsule, injectable, tablet, solution, given by the oral, injection, intravenous route.
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
Recorded notes on how this is sold and what that means for what is in the pack.
No source is stored against this line.
Where it is registered
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No register entry is recorded.
No source is stored against this line.
Why people stop
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
No record of why people stopped taking it is stored for this substance.
No source is stored against this line.
What it would be like to take∅Nothing found in the sources checked
What can go wrong
Sorted by where each line came from. A regulator's label and a report somebody sent in are not the same kind of fact.
∅Nothing found in the sources checked
No harm is recorded against this substance in the sources RNAWiki checked. Finding nothing is not the same as showing there is nothing.
The sources listed were searched and held nothing. That is not the same as nothing existing.
Over a long time. No completed tested study window is recorded, so long-term effects are not established by the registry record.
Groups the studies covered thinly. Which groups were under-represented in the studies has not been recorded for this substance. Pregnancy, breastfeeding, children, older adults, and people with liver or kidney conditions are commonly excluded from trials; nothing here says whether they were.
What is missing or unclear◇Read from sources, not yet reviewed
Does the exact form matter?
Evidence belongs to the exact thing that was tested. A different salt, a different mixture or a different preparation is a different question.
The form that was studied
Oral
✎ Source-linked record
Where this came from
A person wrote this into the record with the study named beside it. No reviewer has signed it off.
The form used in the studies cited on this page.
No source is stored against this line.
What is sold
Not recorded.
∅ Nothing recorded
Where this came from
RNAWiki holds nothing here and says so rather than guessing.
Nothing further is recorded about which forms are sold.
No source is stored against this line.
What is recorded as being sold
108 products list this as an active ingredient in the United States drug directory. 108 of them contain it and nothing else.
FDA National Drug Code directory · 57821-004 · read 2026-08-29
They are sold as capsule, injection, injection, powder, for solution, injection, powder, lyophilized, for solution, injection, solution and injection, solution, concentrate, taken intravenous and oral.
FDA National Drug Code directory · 57821-004 · read 2026-08-29
33 published labels name it as an active ingredient. 33 of them describe this substance alone, which is where its own label text on this page comes from.
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-29
Those labels are classed as human prescription drug.
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-29
Cyclophosphamide is intravenous at 3 DOSAGE FORMS AND STRENGTHS Cyclophosphamide for Injection, USP is a sterile white crystal or crystalline powder available in single-dose vials 500 mg 1 gram 2 grams For Injection, powder: 500 mg, 1 gram, and 2 grams (…, recorded as fda label in effect 2026-02-01 in the United States.
US prescribing information · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · read 2026-08-30
Recorded price in US: 1.12118–1.55529 USD per one unit as the pricing file counts it — a tablet, capsule, patch or single item, across 6 priced products whose strengths and pack forms differ, as of 2026-08-26, paid by retail pharmacies buying the product, as surveyed by the Centers for Medicare & Medicaid Services. It is not a list price, an insurance price, or what anyone pays at a counter..
Recorded source · 2026-08-26 · read 2026-08-28
Evidence carries across two names for one substance. It does not carry across a salt, a mirror form or a mixture.
What it would be like to take◇Read from sources, not yet reviewed
What you could measure
This one is decided with a clinician, so this section holds questions to ask rather than a plan to run.
Self-experiment planning is not offered for a prescription or clinician-supervised medicine. The questions below are for a clinician or pharmacist.
Questions worth asking
Which of the trials of Cyclophosphamide (anhydrous) studied people like me?
What was measured, and for how long?
Was the result a laboratory value or a health outcome?
What would we watch for, and when would we stop?
Tracking can show whether something changed for you. It cannot show what caused it.
RNAWiki records evidence. It does not say whether this substance is right for you.
What is missing or unclear◇Read from sources, not yet reviewed
What nobody knows yet
Open questions, each with why it is open and what would close it.
Missing populations
Which groups were under-represented in the studies has not been recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing long-term data
No completed tested study window is recorded.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
No reviewed conclusion
RNAWiki has not yet published a reviewed conclusion for this use.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Missing interaction studies
No interaction was found in the registers checked. Not finding one is not the same as showing there is none.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Formulation uncertainty
Several salts, forms or products of Cyclophosphamide (anhydrous) are recorded. Results from one form may not transfer to another.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
Mechanism not reviewed
No reviewed mechanism story exists for this substance.
Why it matters. Recorded by the evidence model as a gap on this record.
What would answer it
A study that measures it, and a reviewer to sign it off.
Last checked 2026-09-04. Searched: The sources listed in the receipts at the foot of this page.
What happened in people◇Read from sources, not yet reviewed
Check any of this yourself
Every line above traced back to the study it came from. This is the technical layer, and the vocabulary changes here.
How many documents were read
31 documents were read for this substance.
RNAWiki source record
31 of them state the same volumeOfDistribution, and they agree.
RNAWiki source record
Where else this substance is registered
FDA substance identifier (UNII)
8N3DW7272P
CAS registry number
6055-19-2
PubChem compound
22420
ChEMBL
CHEMBL88
ChEBI
4026
RxNorm concept
3002
EMA substance identifier
100000078558
DrugBank
DB00531
Checks this page had to pass
✓ Passed
Identity resolved
no open identity hold
✓ Passed
No unresolved merge across substance families
no quarantine open
✓ Passed
Every public sentence names a source
The opening statement carries the origin: Written into the record, not signed off.
✗ Not passed
Trial roles classified for highlighted evidence
No registered study is classified as testing this substance.
✓ Passed
No internal keys in reader text
enforced by the copy-contract test over the rendered page
✓ Passed
Safety mode resolved
Suppression classes recorded: S1, S3, S4.
✓ Passed
Canonical metadata present
slug and display name present
What is missing or unclear◇Read from sources, not yet reviewed
How this medicine reached us
Kept near the foot of the page. A historical event moves up only when it changes something about this substance today.
What the approval register records
32 approved applications cover products containing this substance. The earliest was NDA012142, approved 19591116 to BAXTER HLTHCARE.
This order is fixed in code and does not count clicks or time on the page.
What is not here
9 questions this page could not answer
These sections were prepared and left out because there was nothing to put in them. They are listed rather than hidden, so the gaps in this record are visible.
What was measured, goal by goal — found nothing in the sources checked.
How close this is to real life — found nothing in the sources checked.
The path through the body — found nothing in the sources checked.
Felt, measured, or meaningful — found nothing in the sources checked.
How long anything takes — found nothing in the sources checked.
What it may clash with — found nothing in the sources checked.
Other ways to the same goal — found nothing in the sources checked.
Claims that go past the evidence — found nothing in the sources checked.
What changed on this page — found nothing in the sources checked.
The record as stored
The full record, for auditing
Everything above is built from what is below. This layer keeps the technical vocabulary, record identifiers and every stored row, so a reader who wants to check the page can.
Recorded evidence blocks (10)
Q2
On the Cyclophosphamide (anhydrous) label: indicated for what?
"Cyclophosphamide for Injection is an alkylating drug indicated for treatment of adults and pediatric patients with: Malignant Disease s: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides,…": indications and usage on Cyclophosphamide (anhydrous)'s label. DailyMed label · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · 2026-08-30
Q3
3311 registered trials of Cyclophosphamide (anhydrous) — at which phases?
Registered studies posting no result
2358 of 3311
3311 registered studies of Cyclophosphamide (anhydrous): 1898 phase2, 1061 phase1, 578 phase3, 119 na, 64 early phase1, 52 phase4, 40 na or unstated. CLINICALTRIALS_SNAPSHOT · 2026-09-01
"PI left institution"; 509 of 3311 registered studies
Show the evidence
Trial
NCT00002761
withdrawn; "PI left institution"
NCT00002772
terminated; "poor accrual"
NCT00002961
terminated; "poor accrual"
NCT00003060
terminated; "lack of patient accrual"
NCT00003086
terminated; "no participants enrolled in a three year period"
NCT00003152
terminated; "low accrual"
14 further recorded trials
NCT00003194
terminated; "Study enrollment did not meet expected goals"
NCT00003605
withdrawn; "no patient accrual"
NCT00003715
terminated; "Terminated: recruiting or enrolling participants has halted prematurely and will not resume; participants are no longer being examined or treated"
NCT00003852
terminated; "lack of patient inclusion"
NCT00004039
withdrawn; "No patient accruals"
NCT00004114
withdrawn; "Study never opened"
NCT00005090
terminated; "poor accrual"
NCT00005612
terminated; "Low accrual"
NCT00005641
terminated; "low study accrual"
NCT00005834
terminated; "poor accrual"
NCT00005852
terminated; "low accrual"
NCT00005984
terminated; "Study terminated as principal investigator \[PI\] left the university."
NCT00005986
terminated; "Principal investigator left the university."
NCT00005987
terminated; "Withdrawn because treatment guidelines changed"
recorded 2026-09-01 · last checked 2026-09-04
Q5
Human studies of Cyclophosphamide (anhydrous) used Cyclophosphamide 150mg — over how long?
studies of Cyclophosphamide (anhydrous) used the recorded amount. ClinicalTrials.gov · 2026-09-01
20 recorded entries; human; IV; also "Cyclophosphamide 150mg", "Cyclophosphamide 100mg", "Cyclophosphamide 50mg"
Show the evidence
human
NCT00326417
Cyclophosphamide 150mg
NCT00326417
Cyclophosphamide 100mg
NCT00326417
Cyclophosphamide 50mg
NCT00632827
Cyclophosphamide 2000 MG
NCT01985841
Cyclophosphamide: 700mg/m2 for up to 4 cycles from date of first dose
NCT02793544
IV; Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5
14 more recorded rows
humanNCT02793544
IV; Cyclophosphamide 50mg/kg/day IV on Days -2,-1
humanNCT02793544
IV; Cyclophosphamide 50mg/kg/day IV on Days -5,-4
humanNCT02793544
IV; Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4
humanNCT03203005
Cyclophosphamide Injection 1 g
humanNCT03242460
Cyclophosphamide 400mg
humanNCT03295383
Cyclophosphamide 50Mg Oral Tablet
humanNCT03318016
Cyclophosphamide 500 MG
humanNCT03318016
Cyclophosphamide 1000 MG
humanNCT03318016
Cyclophosphamide 3000 MG
humanNCT03318016
Cyclophosphamide 4000 MG
humanNCT04389073
Cyclophosphamide 50 mg
humanNCT04545762
Cyclophosphamide 300mg/m2
humanNCT05108805
Cyclophosphamide 500 mg/m^2/day
humanNCT05158608
Post-transplantation Cyclophosphamide at dose 25 mg/kg/day
recorded 2026-09-01 · last checked 2026-09-04
Q6
Cyclophosphamide (anhydrous)'s half-life is 3 to 12 hours — which schedules were studied?
3 to 12 hours, the half-life Cyclophosphamide (anhydrous)'s label states: "Elimination The elimination half-life (t½) of cyclophosphamide ranges from 3 to 12 hours, and clearance (CL) ranges from 4 to 5.6 L/h." DailyMed label · 1de02105-9c5b-4d11-bddf-bf8450d88b78 · 2026-08-30
Show the evidence
half liferecorded_background.pharmacokinetics
3 to 12 hours hours; Elimination The elimination half-life (t½) of cyclophosphamide ranges from 3 to 12 hours, and clearance (CL) ranges from 4 to 5.6 L/h.
recorded 2026-08-30 · last checked 2026-09-04
Q7
Which running trial of Cyclophosphamide (anhydrous) could settle lifespan?
NCT02406222 measures Progression free survival, reading out 2025-06.
172 open trials; n 124; "Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)"
Show the evidence
Trial
NCT02406222
"Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)"; n 124; "Progression free survival"; 2025-06
NCT03709680
"Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent/Refractory Solid Tumors"; n 128; "Phase 2 open-label, randomized: Event-free survival (EFS) based on Investigator assessment."; 2025-10-18
NCT02299999
"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer"; n 1460; "Progression-free survival in the targeted drug arm compared to standard maintenance therapy arm"; 2025-12
NCT04547049
"A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies"; n 232; "Overall survival (OS)"; 2026-04-01
NCT04390399
"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer"; n 328; "Progression Free Survival (PFS)"; 2026-05-31
NCT03012100
"Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer"; n 280; "Disease-free Survival"; 2026-07-31
14 further recorded trials
NCT04594798
"A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL"; n 39; "Progression Free Survival"; 2026-07-31
NCT01704716
"High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)"; n 3300; "Event Free Survival (R1: MAT therapy)"; 2026-09
NCT05622318
"De-escalated Cyclophosphamide (PTCy) and Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis"; n 56; "The number of subjects who experience GVHD-free survival."; 2026-09
NCT02101853
"Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia"; n 669; "Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients"; 2026-09-16
NCT02112916
"Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma"; n 847; "Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients"; 2026-09-16
NCT02306161
"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma"; n 312; "Event-free Survival"; 2026-09-17
NCT02176967
"Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma"; n 621; "Overall survival (OS) (Strata 1-4)"; 2026-09-30
NCT02166463
"Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma"; n 600; "Event Free Survival (EFS), Where Events Include Disease Progression or Relapse, Second Malignancy, or Death"; 2026-10-03
NCT02048813
"Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma"; n 529; "Progression-free Survival (PFS) Rate at 3 Years"; 2026-10-09
NCT02567435
"Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk Rhabdomyosarcoma"; n 325; "Event-free Survival (EFS)"; 2026-10-27
NCT02877303
"Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia"; n 80; "Relapse-free survival (RFS)"; 2026-11-01
NCT03818334
"Post Transplant Cyclophosphamide in Matched Unrelated Donor Stem Cell Transplantation for Hematological Malignancies"; n 50; "Overall Survival"; 2026-11-01
NCT03517137
"Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study"; n 150; "Modified Progression-free Survival (mPFS) Rate at 2 Years"; 2026-11-16
NCT02066220
"International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma"; n 360; "3-year Event-Free Survival (EFS)"; 2026-12
Q8
Which 705 trials of Cyclophosphamide (anhydrous) posted no result?
Posted no result
705 of 705 completed trials
Registrations
NCT00000596, NCT00000703, NCT00000689, NCT00002461, NCT00000658 and NCT00000801, and 699 more
Completion dates
oldest 1983-01; newest 2024-09-01
Show the evidence
Trial
NCT00000596
1983-01
NCT00000703
1990-03
NCT00000689
1991-03
NCT00002461
1991-07
NCT00000658
1996-02
NCT00000801
1998-04
14 further recorded trials
NCT00003185
1998-07
NCT00002755
1999-06
NCT00002554
1999-12
NCT00002521
2000-02
NCT00003340
2000-02
NCT00003050
2000-03
NCT00003214
2000-04
NCT00002502
2000-05
NCT00003398
2000-05
NCT00002691
2000-06
NCT00004904
2000-07
NCT00003667
2000-08
NCT00309569
2000-09
NCT00005854
2000-10
Q9
At the median, Cyclophosphamide (anhydrous)'s trials enrolled 43 people — anything larger?
Median enrolment
43
Largest enrolment
9350
Registered trials counted
3176
Q10
What do 23785 spontaneous reports say about Cyclophosphamide (anhydrous) — and not say?
These are reports people sent to a regulator. They do not show the medicine caused the reaction. Nobody counted how many people took the medicine and reported nothing. The same event can be reported more than once, and many reports are incomplete. News coverage, lawsuits and new warnings change how often people report. A count is not a rate and not a risk.
Cyclophosphamide (anhydrous) appears in spontaneous reports to regulators. Across the 10 most-reported reaction terms, 23785 reaction mentions were counted: febrile neutropenia 5946; neutropenia 4008; pyrexia 3594; thrombocytopenia 2156. FAERS via Open Targets · CHEMBL1200796 · 2026-06-24
Show the evidence
febrile neutropenia
5946
neutropenia
4008
pyrexia
3594
thrombocytopenia
2156
pancytopenia
1469
leukopenia
1438
4 more recorded rows
disease progression
1420
mucosal inflammation
1342
sepsis
1260
bone marrow failure
1152
recorded 2026-06-24 · last checked 2026-09-04
Q11
Cyclophosphamide (anhydrous) and CYP2A6: shared by which compounds?
ChEMBL 37 — CC BY-SA 3.0 Unported · ChEMBL ATC CC BY-SA · ClinicalTrials.gov — US Government work · Open Targets 26.06 — CC0 · openFDA / DailyMed — US Government work
✗ required summary fields resolved: 4 required field(s) not terminal: Why people use it, Best-supported result, Biggest unanswered question, Human evidence
✓ public claims reviewed: 0 reviewed claim(s); drafts are never rendered
✓ source coverage passed: 5 source rows
✓ no critical contamination: no quarantine open
✓ canonical metadata passed: slug and display name present
✓ no raw internal fields: enforced by the copy-contract test over the rendered page
This is a record of evidence. It is not medical advice, and it does not say this substance suits you. Nothing here says any substance on RNAWiki is appropriate for a child.